Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence

By Strohal Robert  

Journal of Dermatological Treatment, Vol. 24, Iss. 3, 2013-06 ,pp. : 199-208

Informa Healthcare

Access to resources Recommend Favorite

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis

By Lynde Charles  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 1-3

Springer Publishing Company

Access to resources Recommend Favorite

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

By Martin Silas   Feldman Steven R.   Augustin Matthias   Szapary Philippe   Schenkel Brad  

Journal of Dermatological Treatment, Vol. 22, Iss. 3, 2011-06 ,pp. : 138-143

Informa Healthcare

Access to resources Recommend Favorite

A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept

By Lynde Charles W.   Gupta Aditya K.   Guenther Lyn   Poulin Yves   Levesque Annie   Bissonnette Robert  

Journal of Dermatological Treatment, Vol. 23, Iss. 4, 2012-08 ,pp. : 261-267

Informa Healthcare

Access to resources Recommend Favorite

Exfoliative Dermatitis after Long-term Methotrexate Treatment of Severe Psoriasis

By Peters Thorsten   Theile-Ochel Susanne   Chemnitz Jens   Söhngen Dietmar   Hunzelmann Nicolas   Scharffetter-Kochanek Karin  

Acta Dermato-Venereologica, Vol. 79, Iss. 5, 1999-08 ,pp. : 391-392

Medical Journals Limited

Access to resources Recommend Favorite